Compare RYTM & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYTM | QBTS |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.8B |
| IPO Year | 2017 | 2022 |
| Metric | RYTM | QBTS |
|---|---|---|
| Price | $115.68 | $21.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $131.14 | $32.53 |
| AVG Volume (30 Days) | 682.0K | ★ 17.0M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.34 | $81.05 |
| Revenue Next Year | $86.06 | $93.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $74.50 | $12.75 |
| 52 Week High | $122.20 | $46.75 |
| Indicator | RYTM | QBTS |
|---|---|---|
| Relative Strength Index (RSI) | 61.49 | 54.04 |
| Support Level | $98.59 | $16.94 |
| Resistance Level | $122.20 | $22.10 |
| Average True Range (ATR) | 5.42 | 1.34 |
| MACD | 0.83 | 0.40 |
| Stochastic Oscillator | 82.89 | 84.57 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.